AI-driven end-to-end drug discovery company
| Date | Round | Amount |
|---|---|---|
| Jun 2022 | Series D Plus Insilico Medicine, a Hong Kong-based AI drug discovery company, raised $60M in Series D funding from a global syndicate including Warburg Pincus, B Capital Group, Qiming Venture Partners, BOLD Capital Partners, Pavilion Capital and BHR Partners. | $60M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.